title: Reply to Davis and colleagues: Twice weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
authors.forename: J
authors.initials: J
authors.lastname: Barker
authors.forename: Z
authors.initials: Z
authors.lastname: Makatini
authors.forename: J
authors.initials: J
authors.lastname: Millard
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004977:Ethambutol / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013019:South Africa; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin